COMBSecretomics: A pragmatic methodological framework for higher-order drug combination analysis using secretomics.

Area of Science:

• Biochemistry
• Pharmacology
• Bioinformatics

Background:

• Multi-drug treatments are crucial for complex diseases, but current discovery focuses on 2-drug anticancer therapies.
• Existing methods lack the ability to analyze higher-order (more than two) drug combinations using secretomic data.
• Secretomic patterns, representing protein release profiles, are vital for understanding cellular communication in disease.

Purpose of the Study:

• Introduce COMBSecretomics, the first methodological framework for exhaustive second- and higher-order drug combination analysis of secretomic patterns.
• Develop novel, model-free methods for analyzing complex drug mixtures.
• Provide a standardized, reproducible approach applicable to various experimental platforms.

Main Methods:

• Developed COMBSecretomics, a framework for analyzing multi-drug combinations.
• Implemented two novel model-free combination analysis methods: a generalized highest single agent principle and hierarchical clustering.
• Incorporated quality control for outlier elimination and non-parametric statistics for uncertainty quantification.

Main Results:

• Demonstrated the framework's functionality through a proof-of-principle study on cartilage degradation.
• Successfully identified second- and higher-order drug mixtures that modify secretomic patterns.
• Established a standardized, reproducible format for secretomic drug combination analysis.

Conclusions:

• COMBSecretomics is the first framework enabling secretome-related second- and higher-order drug combination analysis.
• The framework can be applied to drug discovery, clinical practice, and understanding disease-related cell communication.
• This methodology expands the scope of drug combination studies beyond current limitations.